1. South Korea Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
HLB bioStep Co.Ltd.

HLB bioStep Co.Ltd.

KKRX:278650
6,530.00
KRW
+770.00
(+13.37%)
-501.28EPS
49.23BMarket Cap
Nov 12Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
35,129.92
61,991.7
162,716.04
3,369.96
3,962.93
4,362.69
4,725.47
5,991.44
3,219.5
3,463.88
4,373.87
1,864
Basic EPS, GAAP
3,182.21
13,528.32
23,926.68
321.67
361.11
618.89
809.35
-70
-10
-510
-1,120
-476.09
Free Cash Flow per Basic Share
-11,308.76
9,545.33
3,000.41
-901
-38.06
516.5
-662.5
29.29
72.29
-1,226.53
60.64
-66.77
Dividend per Share
277.76
- -
- -
- -
- -
- -
83.07
106.28
- -
- -
- -
- -
Book Value per Share
248.88
665.87
1,278.49
1,647.21
3,178.56
3,948.49
4,689.29
4,982.08
6,501.77
6,643.72
5,698.58
5,347.9
Tangible Book Value per Share
248.88
552.39
1,178.61
1,547.33
3,077.77
3,808.89
4,545.87
4,850.15
6,386.57
6,051.33
5,436.59
5,108.9
Basic Weighted Avg Shares
- -
- -
- -
11
12
13
14
14
16
17
17
39
Sales/Revenue/Turnover
6,324
11,158
29,340
37,237
46,040
58,520
64,403
86,277
52,814
58,169
74,050
72,151
Operating Margin (%)
30.78
29.44
16.36
16.07
14.62
15.11
15.92
7.47
-2.25
-22.29
-11.64
-8.7
Depreciation Expense
306
603
815
831
1,430
2,056
3,026
4,103
3,476
4,703
4,731
4,810
Net Income, GAAP
573
2,435
4,314
3,554
4,195
8,302
11,031
-1,008
-164
-8,564
-18,962
-18,428
Effective Tax Rate (%)
22.2
3.47
4.01
13.34
15.28
9.31
10.09
- -
116.65
- -
- -
- -
Profit Margin (%)
9.06
21.82
14.7
9.55
9.11
14.19
17.13
-1.17
-0.31
-14.72
-25.61
-25.54
Working Capital
3,652
2,804
12,600
6,037
17,138
13,200
14,597
99,649
14,731
16,193
12,628
11,720
LT Debt
2,500
2,396
- -
3,000
6,258
3,600
11,273
86,329
2,505
1,890
2,288
2,114
Total Equity
3,123
8,792
16,562
21,502
43,023
55,024
66,361
72,202
103,573
116,814
100,937
96,609
Return on Invested Capital (%)
- -
34.96
29.06
23.09
15.29
14.41
12.22
- -
0.13
- -
- -
- -
Return on Capital (%)
- -
29.47
32.91
17.15
11.76
14.58
14.73
- -
-0.52
- -
- -
- -
Return on Common Equity (%)
- -
42.43
35.37
19.36
13.42
17.38
18.66
-1.49
-0.19
-8.02
-18.22
-18.57

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
28,477
28,750
28,901
LT Borrowings
1,795
1,592
1,615
LT Finance Leases
493
618
499
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
17
17
Market Capitalization
122,820
102,419
49,230

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
60,606
48,842
54,344
Cash, Cash Equivalents & STI
43,343
30,792
35,014
Accounts Receivable, Net
7,549
7,629
7,913
Inventories
1,491
1,754
2,164
Total Current Liabilities
47,978
40,843
42,624
Payables & Accruals
- -
- -
- -
ST Debt
28,477
28,750
28,901
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
49.98%
14.41%
-13.59%
Free Cash Flow
-605.1%
-419.11%
-104.98%
Net Income, GAAP
558.28%
1,016.44%
121.4%
Sales/Revenue/Turnover
35.97%
8.53%
27.3%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11,566
11,925
18,537
16,141
58,169
2025
13,578
17,773
23,974
18,725
74,050
2026
13,485
15,966
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-130
-195
-195
-168.88
-510
2025
-105
-1,200
10
-834.24
-1,120
2026
-120
-202
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jung-Hwan Moon
Full Time Employees
150
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Inchon South Korea
IPO Date
Nov 27, 2019
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
HLB bioStep Co., Ltd. is a South Korea-based non-clinical contract research organization (CRO) and biomedical consulting company specializing in in vivo efficacy evaluation, pharmacokinetic testing, and preclinical research solutions for pharmaceuticals, biotherapeutics, medical devices, and health functional materials. Founded in 2012 and headquartered in Incheon, South Korea, the company operates as a core preclinical research subsidiary within the HLB Group. HLB bioStep Co., Ltd. provides a comprehensive range of non-clinical development services and laboratory solutions, including in vivo disease model efficacy testing across oncology, immunology, central nervous system disorders, metabolic diseases, cardiovascular conditions, and ophthalmology; pharmacokinetic (PK), toxicokinetic (TK), and bioanalytical profiling; medical device biocompatibility, safety, and performance evaluations; non-clinical testing of veterinary medicines, health supplements, and cosmetics; advanced diagnostic imaging and histological pathology services utilizing magnetic resonance imaging (MRI), computed tomography (CT), and optical micro-imaging systems; design, construction, and operational management of laboratory animal research facilities and vivariums; supply of specialized disease animal models and laboratory consumables; and bio-consulting services encompassing non-clinical development strategies, regulatory compliance, and translational drug discovery. The company primarily serves biopharmaceutical developers, multinational pharmaceutical corporations, academic research institutes, and medical technology enterprises across South Korea and international markets. In recent developments, the company rebranded from Notus Co., Ltd. to HLB bioStep Co., Ltd. following its acquisition by and integration into HLB Group to strengthen research synergies across the group's global drug development pipeline. The company has expanded its non-clinical testing portfolio and Songdo research infrastructure to support advanced therapeutic modalities, including antibody-drug conjugates (ADCs), cell and gene therapies (CGTs), and targeted immunotherapies. Additionally, HLB bioStep Co., Ltd. has established strategic research collaborations and open innovation alliances with emerging biotechnology firms to provide integrated preclinical validation, biomarker analysis, and early-stage commercialization consulting.